| Aug 8 |
Nvidia-backed Recursion to acquire Exscientia in all-stock deal
|
| Aug 8 |
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
|
| Aug 8 |
Recursion to absorb Exscientia in ‘techbio’ deal
|
| Aug 8 |
Biotech firm Recursion to buy smaller peer Exscientia for $688 million
|
| Jul 31 |
Why Do Hedge Funds Think That Exscientia plc (EXAI) Will Skyrocket?
|
| Jul 22 |
Big Pharma is forging an increased number of partnerships with artificial intelligence vendors for drug discovery services
|
| Jul 19 |
Exscientia acquires oral CDK7 inhibitor for $20m, plans breast cancer trial
|
| Jul 18 |
Exscientia to acquire full rights to lead asset
|
| Jul 18 |
Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout
|
| Jul 12 |
Amazon (AMZN) Expands AWS Clientele With Exscientia Deal
|
